Cargando…

Prostate imaging features that indicate benign or malignant pathology on biopsy

Accurate diagnosis of clinically significant prostate cancer is essential in identifying patients who should be offered treatment with curative intent. Modifications to the Gleason grading system in recent years show that accurate grading and reporting at needle biopsy can improve identification of...

Descripción completa

Detalles Bibliográficos
Autores principales: Lovegrove, Catherine Elizabeth, Matanhelia, Mudit, Randeva, Jagpal, Eldred-Evans, David, Tam, Henry, Miah, Saiful, Winkler, Mathias, Ahmed, Hashim U., Shah, Taimur T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6178322/
https://www.ncbi.nlm.nih.gov/pubmed/30363462
http://dx.doi.org/10.21037/tau.2018.07.06
_version_ 1783361944802033664
author Lovegrove, Catherine Elizabeth
Matanhelia, Mudit
Randeva, Jagpal
Eldred-Evans, David
Tam, Henry
Miah, Saiful
Winkler, Mathias
Ahmed, Hashim U.
Shah, Taimur T.
author_facet Lovegrove, Catherine Elizabeth
Matanhelia, Mudit
Randeva, Jagpal
Eldred-Evans, David
Tam, Henry
Miah, Saiful
Winkler, Mathias
Ahmed, Hashim U.
Shah, Taimur T.
author_sort Lovegrove, Catherine Elizabeth
collection PubMed
description Accurate diagnosis of clinically significant prostate cancer is essential in identifying patients who should be offered treatment with curative intent. Modifications to the Gleason grading system in recent years show that accurate grading and reporting at needle biopsy can improve identification of clinically significant prostate cancers. Extracapsular extension of prostate cancer has been demonstrated to be an adverse prognostic factor with greater risk of metastatic spread than organ-confined disease. Tumor volume may be an independent prognostic factor and should be considered in conjunction with other factors. Multi-parametric magnetic resonance imaging (MP-MRI) has become an increasingly important tool in the diagnosis and characterization of prostate cancer. MP-MRI allows T2-weighted (T2W) anatomical imaging to be combined with functional and physiological assessment. Diffusion-weighted imaging (DWI) has shown greater sensitivity, specificity and negative predictive value compared to prostate specific antigen (PSA) testing and T2W imaging alone and has a more positive correlation with Gleason score and tumour volume. Dynamic gadolinium contrast-enhanced (DCE) imaging can exhibit difficulties in distinguishing prostatitis from malignancy in the peripheral zone, and between benign prostatic hyperplasia (BPH) and malignancies in the transition zone (TZ). Computer aided diagnosis utilizes software to aid radiologists in detecting and diagnosing abnormalities from diagnostic imaging. New techniques of quantitative MRI, such as VERDICT MRI use tissue-specific factors to delineate different cellular and microstructural phenotypes, characterizing tissue properties with greater detail. Proton MR spectroscopic imaging (MRSI) is a more technically challenging imaging modality than DCE and DWI MRI. Over the last decade, choline and prostate-specific membrane antigen (PSMA) positron emission tomography (PET) have developed as better tools for staging than conventional imaging. While hyperpolarized MRI shows promise in improving the imaging and differentiation of benign and malignant lesions there is further work required. Accurate reading and interpretation of diagnostic investigations is key to accurate identification of abnormal areas requiring biopsy, sparing those in whom benign or indolent disease can be managed by non-invasive means. Embracing and advancing existing technologies is essential in furthering this process.
format Online
Article
Text
id pubmed-6178322
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-61783222018-10-24 Prostate imaging features that indicate benign or malignant pathology on biopsy Lovegrove, Catherine Elizabeth Matanhelia, Mudit Randeva, Jagpal Eldred-Evans, David Tam, Henry Miah, Saiful Winkler, Mathias Ahmed, Hashim U. Shah, Taimur T. Transl Androl Urol Review Article Accurate diagnosis of clinically significant prostate cancer is essential in identifying patients who should be offered treatment with curative intent. Modifications to the Gleason grading system in recent years show that accurate grading and reporting at needle biopsy can improve identification of clinically significant prostate cancers. Extracapsular extension of prostate cancer has been demonstrated to be an adverse prognostic factor with greater risk of metastatic spread than organ-confined disease. Tumor volume may be an independent prognostic factor and should be considered in conjunction with other factors. Multi-parametric magnetic resonance imaging (MP-MRI) has become an increasingly important tool in the diagnosis and characterization of prostate cancer. MP-MRI allows T2-weighted (T2W) anatomical imaging to be combined with functional and physiological assessment. Diffusion-weighted imaging (DWI) has shown greater sensitivity, specificity and negative predictive value compared to prostate specific antigen (PSA) testing and T2W imaging alone and has a more positive correlation with Gleason score and tumour volume. Dynamic gadolinium contrast-enhanced (DCE) imaging can exhibit difficulties in distinguishing prostatitis from malignancy in the peripheral zone, and between benign prostatic hyperplasia (BPH) and malignancies in the transition zone (TZ). Computer aided diagnosis utilizes software to aid radiologists in detecting and diagnosing abnormalities from diagnostic imaging. New techniques of quantitative MRI, such as VERDICT MRI use tissue-specific factors to delineate different cellular and microstructural phenotypes, characterizing tissue properties with greater detail. Proton MR spectroscopic imaging (MRSI) is a more technically challenging imaging modality than DCE and DWI MRI. Over the last decade, choline and prostate-specific membrane antigen (PSMA) positron emission tomography (PET) have developed as better tools for staging than conventional imaging. While hyperpolarized MRI shows promise in improving the imaging and differentiation of benign and malignant lesions there is further work required. Accurate reading and interpretation of diagnostic investigations is key to accurate identification of abnormal areas requiring biopsy, sparing those in whom benign or indolent disease can be managed by non-invasive means. Embracing and advancing existing technologies is essential in furthering this process. AME Publishing Company 2018-09 /pmc/articles/PMC6178322/ /pubmed/30363462 http://dx.doi.org/10.21037/tau.2018.07.06 Text en 2018 Translational Andrology and Urology. All rights reserved.
spellingShingle Review Article
Lovegrove, Catherine Elizabeth
Matanhelia, Mudit
Randeva, Jagpal
Eldred-Evans, David
Tam, Henry
Miah, Saiful
Winkler, Mathias
Ahmed, Hashim U.
Shah, Taimur T.
Prostate imaging features that indicate benign or malignant pathology on biopsy
title Prostate imaging features that indicate benign or malignant pathology on biopsy
title_full Prostate imaging features that indicate benign or malignant pathology on biopsy
title_fullStr Prostate imaging features that indicate benign or malignant pathology on biopsy
title_full_unstemmed Prostate imaging features that indicate benign or malignant pathology on biopsy
title_short Prostate imaging features that indicate benign or malignant pathology on biopsy
title_sort prostate imaging features that indicate benign or malignant pathology on biopsy
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6178322/
https://www.ncbi.nlm.nih.gov/pubmed/30363462
http://dx.doi.org/10.21037/tau.2018.07.06
work_keys_str_mv AT lovegrovecatherineelizabeth prostateimagingfeaturesthatindicatebenignormalignantpathologyonbiopsy
AT matanheliamudit prostateimagingfeaturesthatindicatebenignormalignantpathologyonbiopsy
AT randevajagpal prostateimagingfeaturesthatindicatebenignormalignantpathologyonbiopsy
AT eldredevansdavid prostateimagingfeaturesthatindicatebenignormalignantpathologyonbiopsy
AT tamhenry prostateimagingfeaturesthatindicatebenignormalignantpathologyonbiopsy
AT miahsaiful prostateimagingfeaturesthatindicatebenignormalignantpathologyonbiopsy
AT winklermathias prostateimagingfeaturesthatindicatebenignormalignantpathologyonbiopsy
AT ahmedhashimu prostateimagingfeaturesthatindicatebenignormalignantpathologyonbiopsy
AT shahtaimurt prostateimagingfeaturesthatindicatebenignormalignantpathologyonbiopsy